Valneva SE (NAS:VALN)
$ 4.3307 0.1342 (3.2%) Market Cap: 351.65 Mil Enterprise Value: 398.38 Mil PE Ratio: 0 PB Ratio: 1.60 GF Score: 69/100

Q1 2019 Valneva SE Earnings Call Transcript

May 02, 2019 / 01:00PM GMT
Thomas Lingelbach
Valneva SE - Chairman of the Management Board, President & CEO

Thank you so much. Yes, good day, good morning for those calling in from the U.S., and very warm welcome to our quarter 1 2019 analyst call, this time primarily focused on our financial results. Just a way of reminder, first slide, Valneva's profitable commercial business is funding our key R&D program. This is and has been our business model for a long time.

And we are proud to present also today again that this combined business model was a strong growing commercial business generating cash that we focus in investments for clear programs of high unmet medical needs, primarily, right now, Lyme and chikungunya. We will go through the detail numbers later, but it is fair to say that the growth that we have been expecting has been tremendous.

And when you look at the news flow, followed on the next slide, you see that we have had product sales of EUR 32.8 million, which is a 9% growth at constant exchange rate, primarily driven, of course, by growth in IXIARO, with a total revenue of EUR 34.9 million

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot